The global preterm birth and PROM testing market size is expected to reach US$ 2.1 billion by 2030 from US$ 1.61 billion in 2020 and is expected to grow at an impressive double-digit rate of 3.2% from 2021 to 2030.
The study includes drivers and restraints of this market. The study provides an analysis of the global preterm birth and PROM testing Market for the period 2017-2030, wherein 2021 to 2030 is the forecast period and 2020 is considered as the base year.
The growing cases of preterm birth are the primary factor for the growing demand for preterm birth and PROM testing across the globe. As per the data published by the WHO, around 15 million babies are born preterm annually across the world. Preterm birth and PROM testing helps to detect the premature rapture of fetal membranes in pregnant women. By detecting the raptured fetal membrane, the patient can be treated and prevent the preterm birth. According to WHO, preterm birth is a major factor for the death of children under the age of 5 years. The rate of preterm birth ranges from 5% to 18% in across 184 countries. This rate is projected to increase further in the foreseeable future. Hence, the demand for the preterm birth and PROM testing is expected to grow at a significant pace in the upcoming years.
Download the Sample Pages for More Understanding@ https://www.precedenceresearch.com/sample/1281
| Report Highlights | Details |
| Market Size | USD 2.1 Billion by 2030 |
| Growth Rate | CAGR of 3.2% From 2021 to 2030 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Test Type, End User |
| Regional Scope | North America, APAC, Europe, Latin America, MEAN, Rest of the World |
| Segments Covered | Abbott, Qiagen N.V., Biosynex, Hologic, Cooper Surgical, Sera Prognostics, Medixbiochemica, IQ Products, NX Prenatal, Inc., Clinical Innovations, Inc. |
COVID-19 Impact
The outbreak of COVID-19 led to worldwide lockdown, thereby forcing the population to stay at home. Moreover, transportation was hampered during the lockdown period. However, the COVID-19 positively impacted the market and an upsurge was witnessed in the demand for the preterm birth and PROM testing market. According to CDC, a pregnant women infected with the COVID-19 virus is at higher risk and the chances of preterm birth rises in such condition. This rapidly surged the demand for the preterm birth and PROM testing. However, owing to the supply chain disruptions, the distribution of the PROM test solutions were hampered.
Why should you invest in this report?
If you are aiming to enter the global preterm birth and PROM testing market, this report is a comprehensive guide that provides crystal clear insights into this niche market. All the major application areas for preterm birth and PROM testing are covered in this report and information is given on the important regions of the world where this market is likely to boom during the forecast period of 2021-2030, so that you can plan your strategies to enter this market accordingly.
Besides, through this report, you can have a complete grasp of the level of competition you will be facing in this hugely competitive market and if you are an established player in this market already, this report will help you gauge the strategies that your competitors have adopted to stay as market leaders in this market. For new entrants to this market, the voluminous data provided in this report is invaluable.
- Home(current)
- Reports Store(current)
- Industries(current)
- Our Services(current)
- About Us(current)
- Contact Us(current)
- Home
- Healthcare
- Preterm Birth And PROM Testing Market Size, Report 2021-2030
Preterm Birth and PROM Testing Market Size, Share and Growth Analysis (By Test Type: Ultrasound, Biochemical Markers, Pelvic Exam, Nitazine Test, Uterine Monitoring, Pooling, Ferning Test, and Others; By End User: Diagnostic Laboratories, Hospitals, and Others) - Global Industry Analysis, Trends, Regional Outlook, and Forecast 2021 - 2030
Status : Published | No. of Pages : 150+ | Category : Healthcare
The preterm birth and PROM testing market size was valued at US$ 1.61 billion in 2020 and expected to hit US$ 2.1 billion by 2030 with a CAGR of 3.2% from 2021 to 2030.
Growth Factors
The growing cases of preterm birth are the primary factor for the growing demand for preterm birth and PROM testing across the globe. As per the data published by the WHO, around 15 million babies are born preterm annually across the world. Preterm birth and PROM testing helps to detect the premature rapture of fetal membranes in pregnant women. By detecting the raptured fetal membrane, the patient can be treated and prevent the preterm birth. According to WHO, preterm birth is a major factor for the death of children under the age of 5 years. The rate of preterm birth ranges from 5% to 18% in across 184 countries. This rate is projected to increase further in the foreseeable future. Hence, the demand for the preterm birth and PROM testing is expected to grow at a significant pace in the upcoming years.
Another factor propelling the growth of the preterm birth and PROM testing market is the growing penetration of diagnostic labs and healthcare units especially in the emerging markets. The popularity and adoption of diagnostic centers is increasing due to higher reliability, cost-effectiveness, and faster results. In underdeveloped and emerging nations, the popularity of healthcare and diagnostic centers is increasing rapidly as they provide accurate diagnosis results at low cost. This is one of the key factors driving the growth of the preterm birth and PROM testing market.
| Report Highlights | Details |
| Market Size | USD 2.1 Billion by 2030 |
| Growth Rate | CAGR of 3.2% From 2021 to 2030 |
| Base Year | 2020 |
| Historic Data | 2017 to 2020 |
| Forecast Period | 2021 to 2030 |
| Segments Covered | Test Type, End User |
| Regional Scope | North America, APAC, Europe, Latin America, MEAN, Rest of the World |
| Segments Covered | Abbott, Qiagen N.V., Biosynex, Hologic, Cooper Surgical, Sera Prognostics, Medixbiochemica, IQ Products, NX Prenatal, Inc., Clinical Innovations, Inc. |
COVID-19 Impact
The outbreak of COVID-19 led to worldwide lockdown, thereby forcing the population to stay at home. Moreover, transportation was hampered during the lockdown period. However, the COVID-19 positively impacted the market and an upsurge was witnessed in the demand for the preterm birth and PROM testing market. According to CDC, a pregnant women infected with the COVID-19 virus is at higher risk and the chances of preterm birth rises in such condition. This rapidly surged the demand for the preterm birth and PROM testing. However, owing to the supply chain disruptions, the distribution of the PROM test solutions were hampered.
Test Type Insights
By Test Type, in 2020, the ultrasound dominated the market with around 32% share in terms of revenue of the total market.
Ultrasound is the most common type of test conducted by the doctors to observe developing fetus. Ultrasound is a simple test where sound waves are used to produce images of the fetus inside the womb. It is considered to be the safest and painless test as no needles or injections and ionizing radiations are used. Therefore, the ultrasound is projected to retain its dominance throughout the forecast period.
On the other hand, the biomarker test is estimated to be the fastest growing during the forecast period. This is attributed to the accuracy of the biomarker test. A biomarker test is more accurate and reliable than the ultrasound testing. Moreover, biomarker tests can identify the patients that need urgent care. Further it is inexpensive, reliable, and usable at the POC (Point of Care). All these factors make the biomarker the most opportunistic segment during the forecast period.
End User Insights
By End User, in 2020, the diagnostic laboratories dominated the market with around 45% share in terms of revenue of the total market.
The growing penetration of diagnostic labs all over the globe is positively contributing towards the growth of the preterm birth and PROM testing market. The rising awareness regarding PROM test coupled with rising disposable income and technological advancements in the medical test equipment has fostered the segment growth in the past few years. Moreover, cost-effectiveness has been achieved in the field of PROM testing that drives the growth of this segment.
The others segment includes healthcare units, and others point of care units. This segment is gaining rapid traction due to its increasing penetration across the globe. This segment is estimated to grow at a promising rate during the forecast period.
Regional Insights
North America dominated the preterm birth and PROM market and accounted for the largest revenue share of 38% in 2020. This is attributed to the growing cases of preterm birth rate in U.S. According to CDC (Centers for Disease Control and Prevention), 10% of the babies born in 2019 in US were born preterm. Around 17% of the preterm babies die due to low birth weight. The higher adoption of advanced technologies in the preterm birth and PROM testing has fueled the growth of the market in this region.
On the other hand, Asia Pacific is expected to be the most opportunistic market throughout the forecast period. According to the WHO, over 60% of the preterm birth cases occur in Africa and South Asia. The poor families in this developing region suffer the most. However, the growing awareness regarding the availability of PROM tests is positively impacting the market growth in the Asia Pacific region.
Key Companies & Market Share Insights
The market is moderately fragmented with the presence of several local companies. These market players are striving to gain higher market share by adopting strategies, such as investments, partnerships, and acquisitions & mergers. Companies are also spending on the development of improved and efficient preterm birth and PROM testing solutions. Moreover, they are also focusing on maintaining competitive pricing.
Some of the prominent players in the market include:
- Abbott
- Qiagen N.V.
- Biosynex
- Hologic
- Cooper Surgical
- Sera Prognostics
- Medixbiochemica
- IQ Products
- NX Prenatal, Inc.
- Clinical Innovations, Inc.
Segments Covered in the Report
By Test Type
- Ultrasound
- Biochemical Markers
- Pelvic Exam
- Nitazine Test
- Uterine Monitoring
- Pooling
- Ferning Test
- Others
By End User
- Diagnostic Laboratories
- Hospitals
- Others
Regional Analysis:
The geographical analysis of the global preterm birth and PROM testing market has been done for North America, Europe, Asia-Pacific, and the Rest of the World.
The North American market is again segmented into the US, Canada, and Mexico. Coming to the European market, it can be segmented further into the UK, Germany, France, Italy, Spain, and the rest. Coming to the Asia-Pacific, the global preterm birth and PROM testing Market is segmented into China, India, Japan, and Rest of Asia Pacific. Among others, the market is segmented into the Middle East and Africa, (GCC, North Africa, South Africa and Rest of the Middle East & Africa).
Key Questions Answered by the Report:
- What will be the size of the global preterm birth and PROM testing market in 2030?
- What is the expected CAGR for the preterm birth and PROM testing market between 2021 and 2030?
- Which are the top players active in this global market?
- What are the key drivers of this global market?
- How will the market situation change in the coming years?
- Which region held the highest market share in this global market?
- What are the common business tactics adopted by players?
- What is the growth outlook of the global preterm birth and PROM testing market?
TABLE OF CONTENT
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. Market Dynamics Analysis and Trends
5.1. Market Dynamics
5.1.1. Market Drivers
5.1.2. Market Restraints
5.1.3. Market Opportunities
5.2. Porter’s Five Forces Analysis
5.2.1. Bargaining power of suppliers
5.2.2. Bargaining power of buyers
5.2.3. Threat of substitute
5.2.4. Threat of new entrants
5.2.5. Degree of competition
Chapter 6. Competitive Landscape
6.1.1. Company Market Share/Positioning Analysis
6.1.2. Key Strategies Adopted by Players
6.1.3. Vendor Landscape
6.1.3.1. List of Suppliers
6.1.3.2. List of Buyers
Chapter 7. Global Preterm Birth and PROM Testing Market, By Test
7.1. Preterm Birth and PROM Testing Market, by Test Type, 2021-2030
7.1.1. Ultrasound
7.1.1.1. Market Revenue and Forecast (2017-2030)
7.1.2. Biochemical Markers
7.1.2.1. Market Revenue and Forecast (2017-2030)
7.1.3. Pelvic Exam
7.1.3.1. Market Revenue and Forecast (2017-2030)
7.1.4. Nitazine Test
7.1.4.1. Market Revenue and Forecast (2017-2030)
7.1.5. Uterine Monitoring
7.1.5.1. Market Revenue and Forecast (2017-2030)
7.1.6. Pooling
7.1.6.1. Market Revenue and Forecast (2017-2030)
7.1.7. Ferning Test
7.1.7.1. Market Revenue and Forecast (2017-2030)
7.1.8. Others
7.1.8.1. Market Revenue and Forecast (2017-2030)
Chapter 8. Global Preterm Birth and PROM Testing Market, By End User
8.1. Preterm Birth and PROM Testing Market, by End User, 2021-2030
8.1.1. Diagnostic Laboratories
8.1.1.1. Market Revenue and Forecast (2017-2030)
8.1.2. Hospitals
8.1.2.1. Market Revenue and Forecast (2017-2030)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2017-2030)
Chapter 9. Global Preterm Birth and PROM Testing Market, Regional Estimates and Trend Forecast
9.1. North America
9.1.1. Market Revenue and Forecast, by Test (2017-2030)
9.1.2. Market Revenue and Forecast, by End User (2017-2030)
9.1.3. U.S.
9.1.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.1.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.1.4. Rest of North America
9.1.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.1.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.2. Europe
9.2.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.2. Market Revenue and Forecast, by End User (2017-2030)
9.2.3. UK
9.2.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.2.4. Germany
9.2.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.2.5. France
9.2.5.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.5.2. Market Revenue and Forecast, by End User (2017-2030)
9.2.6. Rest of Europe
9.2.6.1. Market Revenue and Forecast, by Test (2017-2030)
9.2.6.2. Market Revenue and Forecast, by End User (2017-2030)
9.3. APAC
9.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.3.3. India
9.3.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.3.4. China
9.3.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.3.5. Japan
9.3.5.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.5.2. Market Revenue and Forecast, by End User (2017-2030)
9.3.6. Rest of APAC
9.3.6.1. Market Revenue and Forecast, by Test (2017-2030)
9.3.6.2. Market Revenue and Forecast, by End User (2017-2030)
9.4. MEA
9.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.4.3. GCC
9.4.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.4.4. North Africa
9.4.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.4.2. Market Revenue and Forecast, by End User (2017-2030)
9.4.5. South Africa
9.4.5.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.5.2. Market Revenue and Forecast, by End User (2017-2030)
9.4.6. Rest of MEA
9.4.6.1. Market Revenue and Forecast, by Test (2017-2030)
9.4.6.2. Market Revenue and Forecast, by End User (2017-2030)
9.5. Latin America
9.5.1. Market Revenue and Forecast, by Test (2017-2030)
9.5.2. Market Revenue and Forecast, by End User (2017-2030)
9.5.3. Brazil
9.5.3.1. Market Revenue and Forecast, by Test (2017-2030)
9.5.3.2. Market Revenue and Forecast, by End User (2017-2030)
9.5.4. Rest of LATAM
9.5.4.1. Market Revenue and Forecast, by Test (2017-2030)
9.5.4.2. Market Revenue and Forecast, by End User (2017-2030)
Chapter 10. Company Profiles
10.1. Abbott
10.1.1. Company Overview
10.1.2. Product Offerings
10.1.3. Financial Performance
10.1.4. Recent Initiatives
10.2. Qiagen N.V.
10.2.1. Company Overview
10.2.2. Product Offerings
10.2.3. Financial Performance
10.2.4. Recent Initiatives
10.3. Biosynex
10.3.1. Company Overview
10.3.2. Product Offerings
10.3.3. Financial Performance
10.3.4. Recent Initiatives
10.4. Hologic
10.4.1. Company Overview
10.4.2. Product Offerings
10.4.3. Financial Performance
10.4.4. Recent Initiatives
10.5. Cooper Surgical
10.5.1. Company Overview
10.5.2. Product Offerings
10.5.3. Financial Performance
10.5.4. Recent Initiatives
10.6. Sera Prognostics
10.6.1. Company Overview
10.6.2. Product Offerings
10.6.3. Financial Performance
10.6.4. Recent Initiatives
10.7. Medixbiochemica
10.7.1. Company Overview
10.7.2. Product Offerings
10.7.3. Financial Performance
10.7.4. Recent Initiatives
10.8. IQ Products
10.8.1. Company Overview
10.8.2. Product Offerings
10.8.3. Financial Performance
10.8.4. Recent Initiatives
10.9. NX Prenatal, Inc.
10.9.1. Company Overview
10.9.2. Product Offerings
10.9.3. Financial Performance
10.9.4. Recent Initiatives
10.10. Clinical Innovations, Inc.
10.10.1. Company Overview
10.10.2. Product Offerings
10.10.3. Financial Performance
10.10.4. Recent Initiatives
Chapter 11. Research Methodology
11.1. Primary Research
11.2. Secondary Research
11.3. Assumptions
Chapter 12. Appendix
12.1. About Us
12.2. Glossary of Terms
Buy this Premium Research Report@ https://www.precedenceresearch.com/checkout/1281
About Us:
Precedence Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Precedence Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and among different ventures present globally.
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
0 Comments